Fujirebio Diagnostics and Abbott Agree to Develop New Ovarian Cancer Test for Abbott's ARCHITECT® Analyzers

Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop a new ovarian cancer test for use on Abbott's automated ARCHITECT® diagnostic analyzers. Under the agreement, Fujirebio Diagnostics will develop and manufacture for Abbott the HE4 biomarker, a simple blood test that may help in the risk stratification of women at high risk for ovarian cancer, a difficult disease to detect in its early stage.

Malvern, PA, USA - January 27, 2009 - Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop a new ovarian cancer test for use on Abbott's automated ARCHITECT® diagnostic analyzers. Under the agreement, Fujirebio Diagnostics will develop and manufacture for Abbott the HE4 biomarker, a simple blood test that may help in the risk stratification of women at high risk for ovarian cancer, a difficult disease to detect in its early stage.

> View the complete press release (PDF)